Literature DB >> 31667184

Recognizable type of pituitary, heart, kidney and skeletal dysplasia mostly caused by SEMA3A mutation: A case report.

Fang Hu1, Liao Sun2.   

Abstract

BACKGROUND: The SEMA3A gene, which is located at 7q21.11, is involved in hypothalamic neuron migration, heart development, kidney development, and skeleton metabolism. Mutation of the SEMA3A gene is associated with Kallmann syndrome 16 with or without a normal sense of smell. In addition, two case reports showed that mutation of the SEMA3A gene could cause short stature, low gonadotropin, hypogonadism, thoracic deformity, a high scapula, rib and lower limb deformity, facial deformity (long face, epicanthic folds, backwards ears), and arterial malformation. CASE
SUMMARY: We reported the case of a 26-year-old Chinese man who was admitted because of short stature. Physical examination showed that he had many abnormal symptoms, including a short neck, facial moles, knee valgus, transverse palm, continuous grade 5/6 murmurs in the pulmonary auscultation area, no whiskers, or pubic hair, no Adam's apple, short penis and cryptorchidism. Radiological examination showed pituitary, gonad, heart, kidney and skeletal dysplasia. The laboratory tests revealed low growth hormone, luteinizing hormone, follicle-stimulating hormone, testosterone and estrogen. Clinical whole-exome detection showed that our patient, unlike previously reported patients, has a new SEMA3A gene mutation (c.950A>G). Now, his height has increased by 3 cm. In addition, he has a good appetite and reduced subcutaneous fat over 3 mo of recombinant human growth hormone injections therapy. Unfortunately, he refuses further treatment about gonad.
CONCLUSION: Patients who come to a hospital because of their short stature must undergo gene detection if they have other simultaneous abnormal phenotypes. ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Cryptorchidism; Heart dysplasia; Kidney dysplasia; Pituitary dysplasia; SEMA3A; Short stature

Year:  2019        PMID: 31667184      PMCID: PMC6819303          DOI: 10.12998/wjcc.v7.i20.3310

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  8 in total

1.  Bone diseases: SEMA3A strikes a balance in bone homeostasis.

Authors:  Man Tsuey Tse
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Biallelic SEMA3A defects cause a novel type of syndromic short stature.

Authors:  Kristin Hofmann; Markus Zweier; Heinrich Sticht; Christiane Zweier; Wolfgang Wittmann; Juliane Hoyer; Steffen Uebe; Arie van Haeringen; Christian T Thiel; Arif B Ekici; André Reis; Anita Rauch
Journal:  Am J Med Genet A       Date:  2013-10-03       Impact factor: 2.802

3.  A recognizable type of syndromic short stature with arthrogryposis caused by bi-allelic SEMA3A loss-of-function variants.

Authors:  M Baumann; E Steichen-Gersdorf; B Krabichler; T Müller; A R Janecke
Journal:  Clin Genet       Date:  2017-03-19       Impact factor: 4.438

Review 4.  Semaphorins in kidney development and disease: modulators of ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk.

Authors:  Kimberly Reidy; Alda Tufro
Journal:  Pediatr Nephrol       Date:  2011-02-20       Impact factor: 3.714

5.  Characterization of SEMA3A-encoded semaphorin as a naturally occurring Kv4.3 protein inhibitor and its contribution to Brugada syndrome.

Authors:  Nicole J Boczek; Dan Ye; Eric K Johnson; Wei Wang; Lia Crotti; David J Tester; Federica Dagradi; Yuka Mizusawa; Margherita Torchio; Marielle Alders; John R Giudicessi; Arthur A M Wilde; Peter J Schwartz; Jeanne M Nerbonne; Michael J Ackerman
Journal:  Circ Res       Date:  2014-06-24       Impact factor: 17.367

6.  Serum Sema3A is in a weak positive association with bone formation marker osteocalcin but not related to bone mineral densities in postmenopausal women.

Authors:  Dong-mei Liu; Nan Lu; Lin Zhao; Min-jia Zhang; Bei Tao; Yan Xuan; Li-hao Sun; Hong-yan Zhao; Wei-qing Wang; Jian-min Liu; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

7.  Urinary semaphorin 3A correlates with diabetic proteinuria and mediates diabetic nephropathy and associated inflammation in mice.

Authors:  Riyaz Mohamed; Punithavathi Ranganathan; Calpurnia Jayakumar; Ferdau L Nauta; Ron T Gansevoort; Neal L Weintraub; Michael Brands; Ganesan Ramesh
Journal:  J Mol Med (Berl)       Date:  2014-09-25       Impact factor: 4.599

8.  SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome.

Authors:  Naresh Kumar Hanchate; Paolo Giacobini; Pierre Lhuillier; Jyoti Parkash; Cécile Espy; Corinne Fouveaut; Chrystel Leroy; Stéphanie Baron; Céline Campagne; Charlotte Vanacker; Francis Collier; Corinne Cruaud; Vincent Meyer; Alfons García-Piñero; Didier Dewailly; Christine Cortet-Rudelli; Ksenija Gersak; Chantal Metz; Gérard Chabrier; Michel Pugeat; Jacques Young; Jean-Pierre Hardelin; Vincent Prevot; Catherine Dodé
Journal:  PLoS Genet       Date:  2012-08-23       Impact factor: 5.917

  8 in total
  3 in total

Review 1.  State of the Science for Kidney Disorders in Phelan-McDermid Syndrome: UPK3A, FBLN1, WNT7B, and CELSR1 as Candidate Genes.

Authors:  Megan D McCoy; Sara M Sarasua; Jane M DeLuca; Stephanie Davis; Katy Phelan; Roger Curtis Rogers; Luigi Boccuto
Journal:  Genes (Basel)       Date:  2022-06-10       Impact factor: 4.141

2.  A Novel Osteochondrodysplasia With Empty Sella Associates With a TBX2 Variant.

Authors:  Riikka E Mäkitie; Sanna Toiviainen-Salo; Ilkka Kaitila; Outi Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-03       Impact factor: 5.555

Review 3.  Novel genes and variants associated with congenital pituitary hormone deficiency in the era of next-generation sequencing.

Authors:  Hironori Bando; Shin Urai; Keitaro Kanie; Yuriko Sasaki; Masaaki Yamamoto; Hidenori Fukuoka; Genzo Iguchi; Sally A Camper
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.